DFE Pharma appoints Martti Hedman as new CEO 7th February 2022
DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, today announced that Martti Hedman has been appointed as the new Chief Executive Officer. An experienced business leader, Hedman will succeed Bas van Driel and assume responsibilities on 14th February. Van Driel decided to step down in order to allow the company to further grow after setting the company up for success.
Hedman has many years of global business leadership experience in the pharma industry, having lived and held executive positions in the United States, United Kingdom, Germany, and Finland. As former CEO of Colorcon, a global designer and developer of specialty excipients for solid oral dosages for the pharmaceutical and nutritional industries, he is well-known to the industry.
Speaking on behalf of the Governance Board, Herman Ermens of Royal FrieslandCampina, said: “We are very pleased to welcome Martti Hedman to DFE Pharma, an influential and decisive leader with a history of success. Martti will bring a wealth of international experience in the pharma industry as well as a broad range of both industry and customer relationships. We are confident that Martti is very well-placed to take the business to the next level as a global excipient company.”
“I am excited to join DFE Pharma as its new CEO. The company is a global market leader in its excipient categories. I am looking forward to working with all my new colleagues and taking the company to the next phase. I am especially pleased to know that DFE Pharma plays a key role in the COVID-19 therapies – both in vaccines and in solid oral dosage forms”, Hedman adds.